表紙
市場調査レポート

Progenics Pharmaceuticals, Inc.- 製品パイプライン分析

Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 200993
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
Progenics Pharmaceuticals, Inc.- 製品パイプライン分析 Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年05月27日 ページ情報: 英文 36 Pages
概要

Progenics Pharmaceuticals, Inc.は癌治療薬を開発し、製品化するバイオ製薬企業です。同社の製品化第1号であるRELISTOR は、オピオイド誘発性便秘の治療薬として有名です。

当レポートでは、Progenics Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Progenics Pharmaceuticals, Inc.の基本情報

Progenics Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

Progenics Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Progenics Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Progenics Pharmaceuticals, Inc.:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Progenics Pharmaceuticals, Inc.:薬剤プロファイル

  • methylnaltrexone bromide
  • Edotreotide Labeled Yttrium 90
  • iobenguane I 131
  • PSMA ADC
  • MIP-1095
  • MIP-1375
  • MIP-1407
  • PSMA-KLH Conjugate Vaccines

Progenics Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Progenics Pharmaceuticals, Inc.:最近のパイプライン動向

Progenics Pharmaceuticals, Inc.:休止中のプロジェクト

Progenics Pharmaceuticals, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • PRO-206
    • PSMA VRP Vaccine

Progenics Pharmaceuticals, Inc.:企業発表

Progenics Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07132CDB

Summary

Global Markets Direct's, 'Progenics Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Progenics Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progenics Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Progenics Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Progenics Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Progenics Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Progenics Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Progenics Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progenics Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Progenics Pharmaceuticals, Inc. Snapshot
    • Progenics Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Progenics Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Progenics Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Progenics Pharmaceuticals, Inc. - Pipeline Products Glance
    • Progenics Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Progenics Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Progenics Pharmaceuticals, Inc. - Drug Profiles
    • Edotreotide Labeled Yttrium 90
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • iobenguane sulfate I 131
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PSMA ADC
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIP-1095
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Progenics Pharmaceuticals, Inc. - Pipeline Analysis
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Target
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Progenics Pharmaceuticals, Inc. - Dormant Projects
  • Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • PSMA VRP Vaccine
  • Progenics Pharmaceuticals, Inc. - Company Statement
  • Progenics Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Progenics Pharmaceuticals, Inc., Key Information
  • Progenics Pharmaceuticals, Inc., Key Facts
  • Progenics Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Progenics Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Progenics Pharmaceuticals, Inc. - Phase II, 2015
  • Progenics Pharmaceuticals, Inc. - Preclinical, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Progenics Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Progenics Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
  • Progenics Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Progenics Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Progenics Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Progenics Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top